Detalles de la búsqueda
1.
Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases.
Int J Mol Sci
; 24(7)2023 Mar 26.
Artículo
Inglés
| MEDLINE | ID: mdl-37047224
2.
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Alzheimers Dement
; 17(8): 1365-1382, 2021 08.
Artículo
Inglés
| MEDLINE | ID: mdl-33559354
3.
Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
Mov Disord
; 33(8): 1287-1297, 2018 08.
Artículo
Inglés
| MEDLINE | ID: mdl-29701258
4.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
N Engl J Med
; 370(4): 322-33, 2014 Jan 23.
Artículo
Inglés
| MEDLINE | ID: mdl-24450891
5.
First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.
Mov Disord
; 32(2): 211-218, 2017 02.
Artículo
Inglés
| MEDLINE | ID: mdl-27886407
6.
Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
Dement Geriatr Cogn Disord
; 44(3-4): 129-143, 2017.
Artículo
Inglés
| MEDLINE | ID: mdl-28787712
7.
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Dement Geriatr Cogn Disord
; 41(1-2): 80-92, 2016.
Artículo
Inglés
| MEDLINE | ID: mdl-26745445
8.
Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany.
Qual Life Res
; 23(6): 1813-21, 2014 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-24448684
9.
Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?
Alzheimers Dement
; 10(6): 853-60, 2014 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-25458309
10.
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
Alzheimers Res Ther
; 16(1): 20, 2024 01 25.
Artículo
Inglés
| MEDLINE | ID: mdl-38273408
11.
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Alzheimer Dis Assoc Disord
; 27(1): 4-15, 2013.
Artículo
Inglés
| MEDLINE | ID: mdl-23203162
12.
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.
Alzheimers Dement
; 9(1 Suppl): S45-55, 2013 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-22658286
13.
Improving Alzheimer's disease phase II clinical trials.
Alzheimers Dement
; 9(1): 39-49, 2013 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-23164548
14.
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.
Alzheimers Dement
; 9(1 Suppl): S21-31, 2013 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-23127469
15.
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimers Dement
; 9(4): 438-44, 2013 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-23809364
16.
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.
Transl Neurodegener
; 12(1): 54, 2023 11 16.
Artículo
Inglés
| MEDLINE | ID: mdl-37968718
17.
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Alzheimers Dement
; 7(4): 367-85, 2011 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-21784348
18.
Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Neurology
; 96(20): 944-954, 2021 05 18.
Artículo
Inglés
| MEDLINE | ID: mdl-33674360
19.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Nat Med
; 27(8): 1451-1457, 2021 08.
Artículo
Inglés
| MEDLINE | ID: mdl-34385707
20.
A single ascending dose study of bapineuzumab in patients with Alzheimer disease.
Alzheimer Dis Assoc Disord
; 24(2): 198-203, 2010.
Artículo
Inglés
| MEDLINE | ID: mdl-20505438